10-Q · May 15, 2026
Incannex Healthcare reported no revenue for Q3 2026, maintaining a 100% decrease compared to the previous year. The company incurred a net loss of $4.4 million this quarter, a 7% increase in losses compared to the same…
Earnings analysis · 10-K
IXHL earnings analysis
Filed September 25, 2026 · Our reading of the company's report
The latest report
Incannex remains a clinical-stage, pre-revenue biopharmaceutical company focused primarily on IHL-42X for obstructive sleep apnea, with PSX-001 providing a second lead program and encouraging Phase 2 data. Fiscal 2026…
Read full summary
Incannex remains a clinical-stage, pre-revenue biopharmaceutical company focused primarily on IHL-42X for obstructive sleep apnea, with PSX-001 providing a second lead program and encouraging Phase 2 data. Fiscal 2026 financial performance improved substantially, with net loss falling to $19.3 million and cash rising to $67.7 million after $78.7 million of equity issuance proceeds, but the company continues to consume cash and expects additional funding will be needed. The unresolved material weakness, the shift to an additional IHL-42X Phase 2 study, and increasingly advanced OSA competitors keep the outlook balanced despite clinical and liquidity progress.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.66
- Segment
- One reportable and operating segment: research and development of psychedelic medicine and drug therapies; fiscal 2026 revenue was $0.
What stood out
-
IHL-42X remains lead development program
Management identifies IHL-42X for obstructive sleep apnea as the principal development priority. The DReAMzz Phase 2 dose-confirmation crossover study is evaluating nine dose combinations across approximately 120 subjects at 14 U.S. sites, with completion estimated in mid-2027 to inform a planned Phase 3 trial.
-
Positive PSX-001 Phase 2 efficacy signal
PSX-001 Phase 2 results showed an average 12.8-point HAM-A reduction sustained through an 11-week follow-up; 44.1% of treated subjects achieved a greater than 50% reduction and 27% achieved full remission, versus five times lower remission in placebo. The treatment was evaluated across 73 patients with no serious adverse events and one discontinuation.
-
Net loss sharply reduced
The loss trajectory improved materially: net loss declined to $19.3 million in fiscal 2026 from $46.9 million in fiscal 2025, while loss per share improved to $1.66 from $40.82 on a retrospective split-adjusted basis. The improvement was primarily due to $26.9 million of financing-related losses recorded in fiscal 2025 that did not recur to the same extent.
-
Cash balance provides near-term runway
Liquidity strengthened following $78.7 million of share issuance proceeds, partly offset by $9.4 million of share repurchases and $3.1 million of share issuance costs. Cash and cash equivalents increased to $67.7 million at June 30, 2026 from $15.0 million a year earlier, and management expects funding for at least 12 months.
-
R&D incentives support funding
Australian R&D tax incentives increased to $4.7 million in fiscal 2026 from $1.8 million in fiscal 2025, representing a $2.9 million increase. The company also received a final A$5.1 million refund on August 11, 2026, bringing total cash refunds related to the fiscal 2025 claim to more than A$11.2 million.
-
IHL-42X intellectual property advanced
The company received a key USPTO patent for IHL-42X in June 2026 covering the proprietary composition and associated therapeutic methods for obstructive sleep apnea. However, patent protection for PSX-001 remains under exploration rather than established.
What to watch
-
Material weakness remains unresolved
Management concluded that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 because the CFO directs initiation, review and approval of reporting activities without independent review or effective segregation of duties. The company cannot determine when remediation will be completed or assure that it will be successful.
-
Additional Phase 2 delays Phase 3
The company changed its IHL-42X development strategy after deciding not to proceed with the Phase 3 RePOSA design and instead commencing the Phase 2 DReAMzz study in May 2026. DReAMzz is expected to finish only in mid-2027, creating additional timeline and financing risk before a Phase 3 trial can begin.
-
OSA competitors may reach market first
IHL-42X faces an increasingly advanced competitive landscape: Zepbound was approved for obstructive sleep apnea in obese patients, while Apnimed’s AD109 completed Phase 2b and Phase 3 trials and its NDA was accepted by the FDA. The filing warns AD109 could become the first oral pharmacologic OSA therapy before IHL-42X completes development, reducing its addressable market.
-
Continued financing dependence
The company has no product revenue and states that none of its drug candidates has been approved for commercialization. It reported $12.9 million of operating cash outflow in fiscal 2026, expects losses to continue, and says substantial additional capital will be required beyond the current 12-month runway.
-
Delisting risk after reverse split
Nasdaq compliance remains an ongoing trading and financing risk despite the company regaining compliance after a 1-for-30 reverse stock split. The filing states that the stock must maintain a closing bid price of at least $1.00 for 30 consecutive trading days, or the shares could be delisted.
Management's outlook
The 10-K provides no numeric revenue or EPS guidance. Management states that DReAMzz is estimated to be completed in mid-2027 and that current cash is expected to fund planned operating expenses and capital expenditures for at least 12 months from the financial statement date.
Earlier filings 4
10-Q · February 13, 2026
Incannex reported no revenue for the quarter (Revenue from customers $0) and a quarterly net loss of $(6,521) (three months ended December 31, 2025) vs $(5,894) prior-year. Cash increased materially to $68,900 (as of…
10-Q · November 14, 2025
Incannex reported Q1 (three months ended September 30, 2025) revenue of $0 and a net loss of $(6,407), producing EPS of $(0.02) versus prior-year EPS of $(0.29). The company completed a large share issuance that…
10-Q · May 15, 2025
Incannex Healthcare reported a Q3 net loss of $3.968 million (EPS $(0.20)) versus a loss of $6.031 million (EPS $(0.38)) in the prior-year quarter, driven by lower operating expenses and non-cash gains on warrants. The…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.